PHILADELPHIA–(BUSINESS WIRE)–Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at AASLD’s The Liver Meeting®, in Washington…
WASHINGTON — Assessing sustained virological response (SVR) to hepatitis C virus (HCV) therapy at 4 weeks after treatment…
This request seems a bit unusual, so we need to confirm that you’re human. Please press and hold the button until it turns completely green. Thank you for your cooperation!
Cardiovascular outcome trials of the incretin-based medicines tirzepatide and semaglutide have shown benefits in populations with varying levels of cardiovascular risk. However, without direct head-to-head comparisons, treatment decisions rely on…
Adult patients treated for
Data from the Does Eliminating Coffee…
DALLAS, Nov. 9, 2025 — More than 28 million people worldwide are living with heart valve disease, and the numbers are climbing. In the U.S., the condition contributes to more than 60,000 deaths each year. [1] Yet many people are…
NEW ORLEANS, LA—For patients with atrial fibrillation (AF) who are at high risk of both stroke and…
